Leah Neufeld Buys 2,626 Shares of Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation (NASDAQ:IMRX) insider Leah Neufeld acquired 2,626 shares of Immuneering stock in a transaction that occurred on Tuesday, January 13th. The shares were purchased at an average cost of $4.15 per share, for a total transaction of $10,897.90. Following the purchase, the insider directly owned 25,970 shares in the company, valued at $107,775.50. The trade was a 11.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immuneering Price Performance

IMRX traded up $0.18 during mid-day trading on Thursday, hitting $4.61. The stock had a trading volume of 679,229 shares, compared to its average volume of 4,423,273. The stock’s fifty day simple moving average is $6.45 and its 200-day simple moving average is $5.78. The firm has a market capitalization of $297.34 million, a price-to-earnings ratio of -2.59 and a beta of 0.48. Immuneering Corporation has a 1-year low of $1.10 and a 1-year high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, research analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immuneering

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sanofi bought a new position in shares of Immuneering in the 3rd quarter valued at about $18,960,000. Vanguard Group Inc. lifted its stake in Immuneering by 128.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after purchasing an additional 1,358,322 shares during the last quarter. Citadel Advisors LLC bought a new position in Immuneering during the third quarter worth about $6,602,000. Blue Owl Capital Holdings LP acquired a new position in Immuneering during the third quarter worth approximately $3,850,000. Finally, Monashee Investment Management LLC bought a new stake in Immuneering in the third quarter valued at approximately $2,100,000. 67.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IMRX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Mizuho set a $12.00 target price on Immuneering in a report on Wednesday, October 29th. Leerink Partnrs raised Immuneering to a “strong-buy” rating in a research note on Friday, October 31st. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research report on Tuesday, September 30th. Finally, Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.